Ubi Pharma Inc is a Taiwan-based company mainly engaged in development and manufacturing of protein drugs and special dosage-form drugs. The Company is engaged in research and development, manufacturing and sales of protein drugs and special dosage-form drugs, contract manufacturing of pharmaceuticals, and provision of contract research services.

Employees

Sector

Pharmaceuticals

More about the company

End-of-day quote Taipei Exchange 06/05/2024			5-day change	1st Jan Change
14.25 ^TWD	+1.79%		-.--%	-

13/08	UBI Pharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
27/04	UBI Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Market Cap	1.68B 52.76M 45.21M 42.36M 38.7M 73.03M 5.03B 73.75M 500M 195M 2.54B 198M 194M 8.4B	P/E 2024	-9.63x	P/E 2025	-5.68x
Enterprise Value	1.97B 61.82M 52.97M 49.64M 45.34M 85.56M 5.89B 86.41M 585M 228M 2.97B 232M 227M 9.85B	EV / Sales 2024	3.58x	EV / Sales 2025	3.83x
Free-Float	27.79%	Yield 2024 *	-	Yield 2025	-

13/08	UBI Pharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
27/04	UBI Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
12/08/25	UBI Pharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
30/04/25	UBI Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
13/08/24	UBI Pharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2024	CI
18/04/24	UBI Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
11/08/23	UBI Pharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	CI
21/04/23	UBI Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
15/08/22	UBI Pharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2022	CI
29/04/22	UBI Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	CI
29/04/22	UBI Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	CI
16/08/21	Medigen Vaccine Biologics : Taiwan rejects COVID vaccine candidate, president to get domestic shot	RE
16/08/21	Medigen Vaccine Biologics : Taiwan denies approval for UBI's COVID-19 vaccine candidate	RE

3 years	10	38.5
5 years	10	139.55
10 years	8.34	288.72

UBI Pharma Inc. Stock

Stocks

6562

TW0006562002

Pharmaceuticals

Valuation: UBI Pharma Inc.

Latest news : UBI Pharma Inc.

Quotes and Performance

Course Extremes

Managers and Directors: UBI Pharma Inc.

Other Pharmaceuticals

Financials

Company Profile

Manager	Title	Age	Since
Jung Kuang Yang CEO	Chief Executive Officer	-	-
Meng Han Hsu DFI	Director of Finance/CFO	-	11/04/2016
Ying Yun Fan ADM	Chief Administrative Officer	-	01/03/2015

Director	Title	Age	Since
Ying Yun Fan BRD	Director/Board Member	-	30/06/2020
Yan Ning Kuo BRD	Director/Board Member	-	30/06/2020
Yao Hui Wei BRD	Director/Board Member	-	30/06/2020

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
UBI PHARMA INC.	+1.79%	-.--%	-.--%	-55.40%	52.85M
ELI LILLY AND COMPANY	+0.23%	+2.25%	+80.24%	+126.36%	1,111B
JOHNSON & JOHNSON	+0.50%	+0.66%	+52.96%	+64.14%	658B
ABBVIE INC.	+0.60%	+2.83%	+28.28%	+81.51%	467B
ROCHE HOLDING AG	+0.92%	+3.57%	+43.82%	+44.21%	369B
NOVARTIS AG	+1.25%	+2.21%	+26.77%	+43.05%	301B
ASTRAZENECA PLC	+3.02%	+5.68%	+5.09%	+17.04%	256B
AMGEN INC.	+0.18%	+4.33%	+53.81%	+73.07%	240B
NOVO NORDISK A/S	+2.86%	+3.86%	-16.20%	-51.83%	207B
GILEAD SCIENCES, INC.	+0.73%	+2.91%	+29.31%	+92.05%	182B
Average	+1.21%	+4.48%	+30.41%	+43.42%	379.11B
Weighted average by Cap.	+0.84%	+4.68%	+46.86%	+73.31%

	2024	2025
Net sales	539M 16.89M 14.47M 13.56M 12.39M 23.38M 1.61B 23.61M 160M 62.27M 812M 63.42M 62.04M 2.69B	514M 16.13M 13.82M 12.95M 11.83M 22.32M 1.54B 22.54M 153M 59.45M 776M 60.55M 59.23M 2.57B
Net income	-175M -5.47M -4.69M -4.39M -4.01M -7.57M -522M -7.65M -51.81M -20.17M -263M -20.54M -20.09M -871M	-296M -9.29M -7.96M -7.46M -6.81M -12.85M -885M -12.98M -87.96M -34.24M -447M -34.87M -34.11M -1.48B
Net Debt	246M 7.72M 6.62M 6.2M 5.66M 10.69M 736M 10.79M 73.14M 28.47M 371M 28.99M 28.36M 1.23B	289M 9.06M 7.76M 7.27M 6.64M 12.53M 863M 12.66M 85.77M 33.39M 436M 34M 33.26M 1.44B